Nervenheilkunde, Table of Contents Nervenheilkunde 2021; 40(05): 367-376DOI: 10.1055/a-1298-1189 Geist & Gehirn Wen sollen wir impfen? Zur Wissenschaft, Ethik, Moral und zu den Folgen der Priorisierung Manfred Spitzer∗ Recommend Article Abstract Full Text References Literatur 1 Anonymus. Impfdrängler: Koalition plant bis zu 25 000 Euro Strafe. Augsburger Allgemein 25.2.2021. https://www.augsburger-allgemeine.de/politik/Impfdraengler-Koalition-plant-bis-zu-25-000-Euro-Strafe-id59192396.html abgerufen am 2.3.2020 2 Archer SL. Providing care for the 99.9 % during the COVID-19 pandemic: How ethics, equity, epidemiology, and cost per QALY inform healthcare policy. Healthc Manage Forum 2020; 33: 239-242 3 Arolas HPI, Acosta E, López-Casasnovas G. et al Years of life lost to COVID-19 in 81 countries. Sci Rep 2021; 11: 3504 4 Bambery B, Douglas T, Selgelid MJ. et al Influenza Vaccination Strategies Should Target Children. Public Health Ethics 2018; 11: 221-234 5 Briggs AH, Goldstein DA, Kirwin E. et al Estimating (quality-adjusted) life-year losses associated with deaths: With application to COVID-19. Health Econ 2018; 30: 699-707 6 Buonsenso D, Munblit D, De Rose C. et al Preliminary Evidence on Long COVID in children. medRxiv. 2021 7 Campos MR, Schramm JMA, Emmerick ICM. et al Burden of disease from COVID-19 and its acute and chronic complications: reflections on measurement (DALYs) and prospects for the Brazilian Unified National Health Syste. Cad Saude Publica 2020; 36 (11) e00148920 8 Creech CB, Walker SC, Samuels RJ.. SARS-CoV-2 Vaccines. JAMA. 2021 9 Giubilini A, Savulescu J, Wilkinson D. COVID-19 vaccine: vaccinate the young to protect the old?. J Law Biosci 2020; 7: lsaa050 10 Giubilini A, Savulescu J, Wilkinson D.. Queue questions Ethics of COVID-19 vaccine prioritization. Bioethics 2021 11 Hall J, Viney R. Quality adjusted life years in the time of COVID-19. Aust Health Rev 2021; 45: 12-13 12 Halpern SD, Truog RD, Miller FG. Cognitive Bias and Public Health Policy During the COVID-19 Pandemic. JAMA 2020; 324: 337-338 13 Huseynov S, Palma MA, Nayga RM. General Public Preferences for Allocating Scarce Medical Resources During COVID-19. Front Public Health 2020; 8: 587423 14 Jacobs K. et al (Hrsg.) Pflege-Report 2016. „Die Pflegenden im Fokus“. Stuttgart: Schattauer; 2016 15 Kohli M, Maschio M, Becker D. et al The potential public health and economic value of a hypothetical COVID-19 vaccine in the United States: Use of cost-effectiveness modeling to inform vaccination prioritization. Vaccine 2021; 39: 1157-1164 16 Meißner M. Was ist ein Qaly?. Dtsch Arztebl 2010; 107: A-546/B-476/C-468 17 Miles DK, Stedman M, Heald AH. Stay at Home, Protect the National Health Service, Save Lives”: A cost benefit analysis of the lockdown in the United Kingdom. Int J Clin Pract 2020; 13: e13674 18 Moore S, Hill EM, Dyson L. et al Modelling optimal vaccination strateg y for SARS-CoV-2 in the UK. medRxiv. 2020 19 Reddy R. Population health, economics and ethics in the age of COVID-19. BMJ Global Health 2020; 5: e003259 20 Schuppert A. Weber-Carstens S, Karagiannidis C. Simulation der Intensivbettenauslastung für COVID-19 in Abhängigkeit von der Infektionsdynamik und dem zu erwartenden Impfeffekt. 2021 21 Schuppert A, Theisen S, Fränkel P. et al Bundesweites Belastungsmodell für Intensivstationen durch COVID-19. Med Klin Intensivmed Notfmed. 2021 22 Schwinger A, Jürchott K, Tsiasioti C. et al Pflegebedürftigkeit in Deutschland. 2016 23 Shah SMA, Mohammad D, Qureshi MFH. et al Prevalence, Psychological Responses and Associated Correlates of Depression, Anxiety and Stress in a Global Population, During the Coronavirus Disease (COVID-19) Pandemic. Community Ment Health J 2021; 57: 101-110 24 Spitzer M. Öffnet die Schulen. Nervenheilkunde 2021; 40: 296-311 25 Torales J, O’Higgins M, Castaldelli-Maia JM. et al The outbreak of COVID-19 coronavirus and its impact on globalmental health. Int J Soc Psychiatry 2020; 66: 317-320 26 Weekes M, Jones NK, Rivett L. et al Single-dose BNT162b2 vaccine protects against asymptomatic SARS-CoV-2 infection. Authorea 2021 27 Wilkinson D, Zohny H, Kappes A. et al Which factors should be included in triage? An online survey of the attitudes of the UK general public to pandemic triage dilemmas. BMJ Open 2020; 10: e045593 28 Wößmann L. Folgekosten ausbleibenden Lernens: was wir über die coronabedingten Schulschließungen aus der Forschung lernen können. Ifo Schnelldienst 2020; 73: 38-44 29 Wu B. Social isolation and loneliness among older adults in the context of COVID-19: a global challenge. Glob Health Res Policy 2020; 5: 27 30 Raftery R.. Who should be first in line for a covid-19 vaccine?Assessing effectiveness and cost effectiveness. BMJ, Blog, 17.11.2020. https://blogs.bmj.c2020;m/bmj/2020/11/17/james-raftery-who-should-be-first-in-line-for-a-covid-19-vaccine-assessing-effectiveness-and-cost-effectiveness/ abgerufen am 28.1.2021 31 Awad E, Dsouza S, Kim R. et al The Moral Machine experiment. Nature 2018; 563: 59-64 32 Anonymus Impfangebot für alle ab 18 Jahren im Vogtland. MDR 9.3.2021, 18.40 Uhr. https://www.mdr.de/nachrichten/sachsen/chemnitz/vogtland/corona-impfen-ab-achtzehn-100.html abgerufen am 18.3.2021 33 Anonymus. Hof: Stadträte fordern Abkehr von der Impf-Priorisierung. BR24 15.3.2021, 13.44 Uhr. https://www.br.de/nachrichten/bayern/hof-stadtraete-fordern-abkehr-von-der-impf-priorisierung,SRj0mks abgerufen am 19.3.2021 34 Bundesministerium für Gesundheit, BMG (2021) Verordnung zum Anspruch auf Schutzimpfung gegen das Coronavirus SARS-CoV-2 (Coronavirus-Impfverordnung – CoronaImpfV) vom 10. März 2021. Bundesanzeiger herausgegeben vom Bundesministerium für Justiz und für Verbraucherschutz. BAnz AT 11.03.2021 V1 35 Campos MR, Schramm JMA, Emmerick ICM. et al Burden of disease from COVID-19 and its acute and chronic complications: reflections on measurement (DALYs) and prospects for the Brazilian Unified National Health System. Cad Saude Publica 2020; 36 (11) e00148920 36 Feng X, Kim DD, Cohen JT. et al Using QALYsversus DALYs to measure cost-effectiveness:How much does it matter?. International Journal of Technology Assessment in Health Care 2020; 36: 96-103 37 Gold MR, Stevenson D, Fryback DG. HALYs and QALYs and DALYs, Oh My: Similarities and Differences in Summary Measures of Population Health. Annu Rev Public Health 2002; 23: 115-134 38 Bubar KM, Reinholt K, Kissler SM. et al Model-informed COVID-19 vaccine prioritization strategies by age and serostatus. Science 2021; 371: 916-921 39 Medlock J, Galvani AP. Optimizing influenza vaccine distribution. Science 2009; 325: 1705-1708 40 Buss LF, Prete Jr CA, Abrahim CMM. et al Three-quarters attack rate of SARS-CoV-2 in the Brazilian Amazon during a largely unmitigated epidemic. Science 2021; 371: 288-292 41 Logue JK, Franko NM, McCulloch DJ. et al Sequelae in adults at 6 months after COVID-19 infection. JAMA Netw Open 2018; 4: e210830 42 Hansen CH, Michlmayr D, Gubbels SM. et al Assessment of protection against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in Denmark in 2020: a population-level observational study. The Lancet 2021 43 Khamsi R. If a coronavirus vaccine arrives, can the world make enough?. Nature 2020; 580: 578-580 44 Farge E.. WHO says its advisory committee looking at AstraZeneca vaccine issues. Reuters, 12.3.2021. https://www.reuters.com/article/health-coronavirus-who-vaccines/update-2-who-says-its-advisory-committee-looking-at-astrazeneca-vaccine-issues-idUSL8N2LA34M abgerufen am 12.3.2021 45 Ftzpatrick MC, Galvani AP. Optimizing age-specific vaccination. Vaccination strategies are not one-size-fits-all. Science 2021; 371: 890-892 46 Anonymus. FEARS around blood clot links with the AstraZeneca Covid vaccine have sent Europe into a panic. The Sun, 16.3.2021. https://www.thesun.co.uk/news/14350112/boris-johnson-oxford-astrazeneca-jab-safe-eu-ban/ abgerufen am 16.3.2021 47 Oldenburg J, Klamroth R, Langer F. et al Aktualisierte Stellungnahme der GTH nach dem Beschluss der EMA, die Impfungen mit dem AstraZeneca COVID-19 Vakzin fortzusetzen. Gesellschaft für Thrombose- und Hämostaseforschung, 19.3.2021. https://gth-online.org/wp-content/uploads/2021/03/GTH_Stellungnahme_AstraZeneca_3_19032021-3.pdf abgerufen am 22.3.2021
